Valuation: Amicus Therapeutics, Inc.

Market Cap 4.55B 4.08B 3.77B 3.41B 6.36B 433B 6.45B 45.07B 17.96B 227B 17.07B 16.71B 718B P/E 2024
-51.1x
P/E 2025 -162x
Enterprise Value 4.7B 4.21B 3.89B 3.53B 6.57B 447B 6.66B 46.54B 18.54B 234B 17.63B 17.26B 741B EV / Sales 2024
5.69x
EV / Sales 2025 7.18x
Free-Float
99.31%
Yield 2024 *
-
Yield 2025 -
1 day+0.21%
Current year+1.76%
Current year 14.2
Extreme 14.205
14.5
1 year 8.62
Extreme 8.62
14.5
3 years 5.51
Extreme 5.51
14.57
5 years 5.51
Extreme 5.51
14.57
10 years 4.41
Extreme 4.41
25.39
Date Insider Type Main position Quantity % Market Cap. Importance
4/27/26 Issuer sale

General Counsel

1,264,993 0.4029%
4/27/26 Issuer sale

Director

395,940 0.1261%
4/27/26 Issuer sale

Chairman

419,487 0.1336%
Change 5-day change 1-year change 3-year change Capi.($)
+0.21%-.--%+63.18%+35.29% 4.55B
+0.65%-3.56%+33.53%+60.50% 63.48B
+1.76%+2.10%+12.10%+81.21% 54.55B
-0.94%+0.77%+8.85%+100.19% 53.59B
+2.76%+4.18%+28.34%+55.07% 44.75B
+2.00%-2.90%+18.37%+119.04% 41.62B
+1.34%-3.98%+225.44%+914.08% 39.91B
+0.64%-3.85%+11.71%+45.57% 32.47B
+29.06%+48.65%+106.84%+92.73% 26.7B
+3.72%-7.45%+24.25%-2.99% 23.36B
Average +4.12%-0.35%+53.26%+150.07% 38.5B
Weighted average by Cap. +3.20%-0.28%+47.74%+159.98%

Financials

2024 2025
Net sales 528M 474M 437M 396M 739M 50.3B 749M 5.23B 2.08B 26.32B 1.98B 1.94B 83.36B 634M 568M 525M 476M 887M 60.38B 899M 6.28B 2.5B 31.6B 2.38B 2.33B 100B
Net income -56.11M -50.29M -46.45M -42.1M -78.46M -5.34B -79.55M -556M -221M -2.8B -210M -206M -8.85B -27.11M -24.3M -22.44M -20.34M -37.91M -2.58B -38.44M -269M -107M -1.35B -102M -99.57M -4.28B
Net Debt 194M 174M 160M 145M 271M 18.44B 275M 1.92B 764M 9.65B 727M 711M 30.56B 149M 133M 123M 112M 208M 14.17B 211M 1.47B 587M 7.42B 558M 547M 23.48B
Projected Income Statement - Annual - Amicus Therapeutics, Inc.
Logo Amicus Therapeutics, Inc.
Amicus Therapeutics, Inc. is a global biotechnology company focused on discovering, developing and delivering medicines for people living with rare diseases. Its two marketed therapies are Galafold, the first oral monotherapy for people living with Fabry disease who have amenable genetic variants, and Pombiliti + Opfolda, a two-component treatment for adults living with late-onset Pompe disease. As an orally miglustat monotherapy, Galafold is designed to bind to and stabilize an endogenous alpha-galactosidase A enzyme in those patients with genetic variants identified as amenable in a Good Laboratory Practice cell-based amenability assay. Pombiliti + Opfolda consists of an engineered rhGAA enzyme, cipaglucosidase alfa-atga, with an optimized carbohydrate structure to enhance cellular uptake, administered intravenously in combination with orally administered miglustat. In addition, clinical studies are ongoing in pediatric patients for both the LOPD and IOPD populations.
Employees
511
Trader
-
Investor
-
Global
-
Quality
-
ESG MSCI
B
MarketScreener Ratings - Amicus Therapeutics, Inc.
  1. Stock Market
  2. Stocks
  3. FOLD Stock